• Hotline +852 3480 8393

Logo
EN
繁中
  • Home
  • About Us
    • Background
    • Immunotherapy in Japan
    • Immunotherapy in Hong Kong
    • Specialist Consultation
  • Immune Cell Therapy
    • What Is Immune Cell Therapy?
    • Dendritic Cell (DC) Therapy
    • Lymphokine-Activated Killer Cell (LAK) Thearpy
    • Natural Killer Cell (NK) Therapy
    • Success Rate
    • Side Effects
    • Fees
  • Doctor
    • Japan
  • Our News
  • Contact Us
  • EN
    • 繁中
Home > Our News > News > Japanese Media Interview with a Renowned Physician: “The Current Status of Late-Stage Healthcare in Japan”

Japanese Media Interview with a Renowned Physician: “The Current Status of Late-Stage Healthcare in Japan”

  • Japanese Media
  • 2023-10-27
  • 28951 View

Shin-Yokohama Kato Clinic’s Integrated Approach

Led by Dr. Yoichi Kato, Shin-Yokohama Kato Clinic in Yokohama’s Kohoku Ward near Shin-Yokohama Station offers both standard and advanced therapies to numerous patients. We discussed the realities of late-stage healthcare and more with Dr. Kato.


日媒名醫訪問


Progress in Cancer Treatment: The Era of Personalized Therapies

“Cancer treatments have been advancing rapidly, with personalized therapy emerging to tailor optimal care for each patient. What do you see as the most significant change recently?”

Traditionally, cancer treatment options were dictated by the cancer’s location, its stage, and the patient’s prior treatment history. However, these conventional approaches have certain limitations. Increasingly, we are focusing on cancer’s underlying causes—such as immune function and genetic mutations—since cancer often develops when the immune system fails or specific genes mutate. The disease’s nature and treatment strategies both hinge on these genetic and immune factors. Moving forward, highly customized treatments selecting the best option for each patient will be at the forefront—a direction the government strongly supports.


The Significance of Genetic Screening & Existing Challenges

More and more genes have been identified as risk factors for cancer. Take lung cancer as an example: only about 1% of patients have a specific genetic mutation; however, for this group, there is a treatment method that proves effective in 80% of cases. Consequently, if a patient is diagnosed with cancer but does not undergo comprehensive genetic testing, they might miss out on the therapy most likely to succeed.


Another systemic shortfall comes into play when a drug with an 80% effectiveness rate lies outside public insurance coverage, forcing patients to pay an exorbitant out-of-pocket expense. For most people, such costs can be prohibitive—an unfortunate paradox where knowledge of an effective therapy may unsettle patients who cannot afford it. Sustaining overall health and well-being remains critical for late-stage patients facing these dilemmas.


Patient Considerations: Beyond Standard Therapy

“What should patients keep in mind?”

Consolidated guidelines govern standard cancer treatments, and once these prove ineffective, patients typically pivot to palliative care—unfortunately extinguishing hope for many. In reality, there are still numerous approaches worth exploring beyond standard regimens. As medical professionals, our mission is to provide patients with as many avenues of survival and recovery as possible.


Granted, it is often extremely difficult to treat Stage IV or terminal cancer. While chemotherapy may shrink a tumor, it may also damage the liver and brings adverse effects. Using narcotic pain relief helps manage pain but decreases appetite, necessitating careful nutrition oversight. Treatment thus cannot be a simple one-time intervention; it is a prolonged, multi-faceted endeavor. Nevertheless, I find my greatest reward in seeing late-stage cancer recede, allowing patients to regain health and comfort.


What Is Needed for Treating Late-Stage Patients

Many terminal patients ultimately succumb to complications rather than the primary cancer itself. While reducing or controlling the tumor is vital, preserving systemic health is equally important. Even the most advanced drugs fall short if the overall condition of the body steadily deteriorates.


Essential measures include sufficient nutrition, restful sleep, and mild exercise to maintain as much baseline physical function as possible. Even for a bedridden Stage IV patient, being able to awaken when hungry, walk short distances, and eat independently can be pivotal. While palliative care commonly focuses on pain management, sustaining whole-body functionality can significantly influence outcomes and the time patients have, presenting broader prospects and hope for those in advanced stages of cancer.


日媒名醫訪問


Previous:“Humanity’s Innate Immune Power Surpasses Any Manufactured Drug” – Dr. Yoichi Kato, Pioneer in Immunotherapy Next:The Key Differences Among DC, LAK, and NK Immunotherapies—and How to Choose

Category

  • News 18

Latest Articles

  • YouTube channel “珍心活” interviews Dr. Yoichi Kat
    2025-08-03
  • Celebrity Host Cheng Tan Shui’s Exclusive Interview with Connie Lam: How to Choose the Right Doctor in Japan for Immunocellular Therapy
    2025-01-10
  • Hong Kong Actor Carlos Chan Accompanies His Mother to Shin-Yokohama Kato Clinic for Immunotherapy, Expresses Gratitude to Dr. Yoichi Kato
    2024-07-03
  • Yoshida Family Donates 12,000 Square Feet of Land to Dr. Yoichi Kato
    2024-04-05
  • がんの先進医療 | 2025 Jan. vol. 56
    2025-04-02
  • Dr. Kato’s New Medical Facility Nears Completion
    2024-01-19
  • Dr. Kato’s Expert Team: Meet the Visionary Scientist Behind the “Magic Lab”
    2023-11-10
  • “Humanity’s Innate Immune Power Surpasses Any Manufactured Drug” – Dr. Yoichi Kato, Pioneer in Immunotherapy
    2023-11-03
  • Japanese Media Interview with a Renowned Physician: “The Current Status of Late-Stage Healthcare in Japan”
    2023-10-27
  • The Key Differences Among DC, LAK, and NK Immunotherapies—and How to Choose
    2023-10-19
  • Dendritic Cell Vaccine Therapy: Insights from Dr. Yoichi Kato, Immunotherapy Specialist
    2023-08-09
  • Japan’s Leading Expert in Immunotherapy: Dr. Yoichi Kato
    2023-07-27
  • Natural Killer Cells in the Immune System: Your Body's First Line of Defense
    2025-10-13
  • Dendritic Cells Immune Response: The Commanders of Your Immune System
    2025-10-13
  • Dendritic Cells: Defining the Commanders of the Immune System and Their Role in Immunotherapy
    2025-10-13
  • Dendritic Cell Therapy Success Rate: An Evidence-Based Analysis
    2025-10-13
  • Dendritic Cell Therapy: An Advanced Cancer Treatment for Stage 4 Patients
    2025-10-13
All Articles
Logo
  • Email:info@asiaimmune.com
  • Tel / WhatsApp:+852 3480 8393
  • Wechat:aicl_hk
  • Office hours:Mon to Fri | 9am to 6pm

Immune Cell Therapy

  • What Is Immune Cell Therapy?
  • Dendritic Cell (DC) Therapy
  • Lymphokine-Activated Killer Cell (LAK) Thearpy
  • Natural Killer Cell (NK) Therapy
  • Success Rate
  • Side Effects
  • Fees

Address

  • Room 1202, 12/F, Hing Wai Building, 36 Queen's Road Central, Central, HK (📍Goolge Map)
  • +852 3480 8393

Copyright © 2026. Designed by Asia Immunotherapy Company Limited.